HK IPOAI

VIGONVITA-B

0263018AListed

醫療健康 · 苏州旺山旺水生物医药股份有限公司是一家专注于创新药物研发的生物医药公司。

VIGONVITA-B (旺山旺水-B) (02630) is a listed Hong Kong IPO. This page brings together the offer price, entry fee, subscription timeline, grey-market context, allotment data and stage-based reference research in one place.

Offer price
HK$33.37
Final offer price
HK$33.37
One-lot win rate
1.7%

Predicted 1.3%

Proceeds
HK$587.2M
Public oversub.
6238.4x

Lot / entry fee 200 shares · HK$7K · Sponsor CITIC Securities

  1. Offer starts Oct 28
  2. /Offer closes Nov 3
  3. /Grey market Nov 5
  4. /Listing Nov 6Now

SubscriptionVIGONVITA-B: subscription-stage reference

The subscription stage draws on the prospectus, sponsor record and early public filings. Allotment results and grey-market prints have not occurred yet.

Earlier stage
Reference rating
Neutral
Reference score
70.9
Forecast grey range
+31.7% – +176.5%

Pre-greyVIGONVITA-B: pre-grey-market reference

The pre-grey stage includes published allotment and public oversubscription data. Grey-market prints are not yet reflected here.

Earlier stage
Reference rating
High attention
Reference score
75.6
Forecast grey range
+31.4% – +175.2%

Post-greyVIGONVITA-B: post-grey-market reference

The post-grey stage includes grey-market price and turnover observations. Listing-day results still follow official trading and company announcements.

Current
Reference rating
High attention
Reference score
79.6
Forecast first-day range
+149.6% – +212.9%
View factors and research
Model forecastListing-day trendPositiveUp probability 91.8%
Published outcome check
First-day resultBig up+145.7%
Our call: Trend call valid
Covered 18/25 core factors
UsedMissingNot yet scorableN/A
Margin oversubscription
High heat
Offer size
Good quality
Cornerstone lockup
Post-lockup offer value
Recent same-rule trend
Strong trend
Recent same-type trend
Strong trend
Recent sector trend
Strong trend
Valuation
Average appeal
Fundamental quality
Average quality
Growth quality
Weak quality
Profitability
Weak quality
Cash runway
Weak quality
Customer concentration
High risk
Cornerstone quality
Sponsor record
Strong record
Greenshoe arrangementGreenshoe: yes · 15%
Average support
Stabilizer track recordCLSA
Strong record
A-share pre-grey trend
A-share listing-day trend
Public oversubscription
High heat
One-lot win rate
High heat
International placing
High heat
Final pricing position
Actual greenshoe use
Grey market return
Strong trend

The assessment and probability ranges are informational only and are not investment advice.

AI Research Report

Post-grey
The analysis report for this IPO is being generated.

Last updated 18:35:04

HK$85.00
+154.72%
91.2059.1927.17HK$33.3716:1518:35
Listing price
HK$33.37
Open
High
Low
Bid / Ask
— / —
Volume
Turnover View source

VIGONVITA-B: predicted allotment

Only key tiers are shown here. Full tiers and other allotment-pattern comparisons are on the allotment-odds page.

1 lot
1.3%

Official 1.7%

A tail · Apply 700 lots
0.11 lots

Official 0.04 lots

B head · Apply 800 lots
0.15 lots

Official 0.21 lots

Top hammer
0.21 lots

Official 0.22 lots

Most likely allotment patternLarger Pool A applications get less extra allotmentPool B high-tier allotment drops quicklyView full allotment-odds research

How to read this page

These answers combine this IPO’s published figures with clearly labeled model estimates. They explain how to read the modules above and are not investment advice.

What is the one-lot allotment rate for VIGONVITA-B?

Public allotment filings put the official one-lot rate at 1.7%, versus this site's pre-allotment model estimate of 1.3%. It is an observation for a 1-lot application, not a guaranteed result.

What is the difference between A-tail and B-head for VIGONVITA-B?

Based on the prospectus's legal application tiers, A-tail is 700 lots and B-head is 800 lots, representing about HK$4.7M and HK$5.3M of application principal. Official average allotment was 0.04 lots and 0.21 lots, versus pre-allotment model estimates of 0.11 lots and 0.15 lots. Pool A and Pool B are allocated separately, so application size alone does not show capital efficiency.

Can the grey-market price of VIGONVITA-B be treated as the listing price?

The compiled grey-market observation is about +154.7%, versus +145.7% on the listing day. Grey-market prints are pre-listing sentiment from public sources, not the official opening price.

Why does VIGONVITA-B have three reference ratings?

The current status is "Listed", so start with the post-grey section. Subscription, pre-grey and post-grey each use only the public information available at that point, so the score can change. Labels are high attention / neutral / caution only — informational comparison, not a buy or subscribe call.